The AI drug discovery sector achieved its first major clinical validation in 2025 with Insilico Medicine's rentosertib becoming

Biotech dealmaking surged this week, from Pfizer’s $7.3 billion obesity acquisition to a run of licensing, royalty financings,

Overview Milestone payments are contingent fees in pharmaceutical and biotech deals that become due when a product achieves specific goals.

Introduction and Company Overview Revolution Medicines (NASDAQ: RVMD) is a late-stage oncology biotech focused on targeting the RAS oncogene family,

Executive Summary Breakout Ventures is a San Francisco-based venture capital firm specializing in life sciences and "deep tech"

Current Market Dynamics and Transaction Volume The biotech venture debt market underwent substantial transformation following the Silicon Valley Bank collapse

The biopharma sector in 2025 is navigating a difficult funding landscape. Public markets have cooled off after the boom of

1. Historical Examples of Disease-Linked Bonds Pandemic Bonds (World Bank PEF) The most prominent example is the World Bank'

The week of September 15-20, 2025 witnessed over 40 distinct biotech pharmaceutical transactions totaling more than $6 billion in disclosed

In boardrooms and biotech conferences alike, one phrase has become inescapable: “our AI-powered platform.” Startups in drug discovery, clinical decision